BioSpace News Archive

The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that that the European Medicines Agency (EMA) has granted both PRIME (PRIority MEdicines) and Advanced Therapy Medicinal Product (ATMP) designations to the company’s adeno-associated virus (AAV)-RPGR gene therapy product

NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, today announced it will participate at Spine Summit 2020, the 36 th Annual Meeting of the Section on Disorders of the Spine and Peripheral Nerves on March 5-8, 2020

New High-Performance Thermal Analysis, Rheology and Microcalorimetry Tools Help Accelerate the Pace of Materials Research

Sangamo Therapeutics, Inc., a genomic medicine company, announced that management will present at the following investor conferences

Cannabix Technologies Inc. (CSE: BLO) (OTC PINK: BLOZF) (the “Company” or “Cannabix”) developer of marijuana breathalyzer devices for law enforcement and the workplace reports that a significant technological development has been achieved with its FAIMS- (field asymmetric waveform ion mobility spectrometry) marijuana breathalyzer prototype

AnaptysBio today reported operating results for the fourth quarter and year ended December 31, 2019 and provided pipeline updates.

ORIC Pharmaceuticals, Inc., a privately held, clinical-stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced the appointment of Mardi C. Dier to its board of directors.

Neogen Corporation (NASDAQ: NEOG) announced today that it has acquired the food safety assets of Australia-based Cell BioSciences — a major supplier of food safety and industrial microbiology products.

Yuyu Pharma (COO Robert Wonsang Yu, KRX 000220) announced today a review of its compliance policies and procedures with the support of the law firm, Kim & Chang.

Eyevance Pharmaceuticals, committed to developing and commercializing innovative and impactful ophthalmic products, is pleased to announce the United States launch of TOBRADEX® ST (tobramycin/dexamethasone ophthalmic suspension) 0.3%/0.05% following the Company’s acquisition of the product in late 2019.